Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)
Authors
Keywords
Atherosclerotic cardiovascular disease, triglycerides, icosapent ethyl, viral upper respiratory infection, coronavirus disease 2019, seasonal flu
Journal
AMERICAN HEART JOURNAL
Volume 235, Issue -, Pages 54-64
Publisher
Elsevier BV
Online
2021-01-29
DOI
10.1016/j.ahj.2021.01.018
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia
- (2020) Qun Li et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid
- (2020) R. Preston Mason et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California
- (2020) Laura C. Myers et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- From Containment to Mitigation of COVID-19 in the US
- (2020) Stephen M. Parodi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy
- (2020) Graziano Onder et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- (2020) Fei Zhou et al. LANCET
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
- (2020) Jason D. Goldman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Beyond cardiovascular medicine: potential future uses of icosapent ethyl
- (2020) Deepak L Bhatt et al. EUROPEAN HEART JOURNAL SUPPLEMENTS
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
- (2020) Christoph D. Spinner et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The COVID-19 pandemic: a catalyst to improve clinical trials
- (2020) Prakriti Gaba et al. Nature Reviews Cardiology
- Developing Safe and Effective Covid Vaccines — Operation Warp Speed’s Strategy and Approach
- (2020) Moncef Slaoui et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk
- (2020) Stephen J. Nicholls et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT
- (2019) Deepak L. Bhatt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles
- (2019) Deepak L. Bhatt et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- REDUCE-IT USA: Results from the 3,146 Patients Randomized in the United States
- (2019) Deepak L. Bhatt et al. CIRCULATION
- Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial
- (2018) Stephen J. Nicholls et al. CLINICAL CARDIOLOGY
- Marine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
- (2018) JoAnn E. Manson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
- (2018) Deepak L. Bhatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative Effectiveness of Statin Therapy in Chronic Kidney Disease and Acute Myocardial Infarction: A Retrospective Cohort Study
- (2015) David H. Smith et al. AMERICAN JOURNAL OF MEDICINE
- Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester): Effects Upon High-Sensitivity C-Reactive Protein and Lipid Parameters in Patients With Metabolic Syndrome
- (2015) Harold E. Bays et al. Metabolic Syndrome and Related Disorders
- Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies
- (2013) Harold E. Bays et al. American Journal of Cardiovascular Drugs
- Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200–500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study
- (2013) Eliot A Brinton et al. Cardiovascular Diabetology
- Chronic Kidney Disease and Outcomes in Heart Failure With Preserved Versus Reduced Ejection Fraction
- (2013) David H. Smith et al.
- Highly Purified Eicosapentaenoic Acid Increases Interleukin-10 Levels of Peripheral Blood Monocytes in Obese Patients With Dyslipidemia
- (2012) N. Satoh-Asahara et al. DIABETES CARE
- The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease
- (2011) JoAnn E. Manson et al. Contemporary Clinical Trials
- In Vivo and In Vitro Inhibition of Monocyte Adhesion to Endothelial Cells and Endothelial Adhesion Molecules by Eicosapentaenoic Acid
- (2008) Hideto Yamada et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now